The DOI matches its Crossref record; 368 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,934
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 401–500 of 1,279
Role of immune dysfunction in drug induced liver injury
Girish, C., & Sanjay, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1677 · Cited by 10
Drug-Induced Acute-on-Chronic Liver Failure
Ma, J., Ghabril, M., & Chalasani, N. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.03.007 · Cited by 10
de Tymowski, C., Dépret, F., Dudoignon, E., Moreno, N., Zagdanski, A., Hodjat, K., Deniau, B., Mebazaa, A., Legrand, M. M., & Mallet, V. O. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100950 · Cited by 10
Björnsson, H. K., & Bjornsson, E. S. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2288260 · Cited by 10
García‐Cortés, M., Toro-Ortiz, J. P., & García-García, A. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00034 · Cited by 10
Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update
Boyles, T. H., Berhanu, R. H., Gogela, N. A., Gunter, H. M., Lovelock, T., Mphothulo, N., Parker, A., Rabie, H., Richards, L., Sinxadi, P., et al. (2024) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v25i1.1558 · Cited by 10
Song, L., Zhang, Y., Sun, F., Lan, Y., Tong, J., Ge, S., Feng, Z., Li, R., Yu, H., Li, Y., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107230 · Cited by 10
Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database
Ye, W., Ding, Y., Li, M., Tian, Z., Wang, S., & Liu, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317680 · Cited by 10
Ikewuchi, C. C., Ikewuchi, J. C., Ifeanacho, M. O., Jack, D. P., Ikpe, C. N., Ehiosun, S., & Ajayi, T. B. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000143 · Cited by 10
Liu, Y., Xue, Y., Zhang, Z., Ji, J., Li, C., Zheng, K., Lu, J., Gao, Y., Gong, Y., Zhang, Y., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202200945r · Cited by 10
Haraguchi, M., Nakao, Y., Narita, S., Matsumoto, K., Fukushima, M., Sasaki, R., Honda, T., Miuma, S., Miyaaki, H., & Nakao, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5816 · Cited by 10
Liatsos, G. D. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2397 · Cited by 10
Yamamoto, T., Mizuno, K., Ito, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Ishikawa, T., Kanamori, A., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01366-3 · Cited by 10
Li, M., Wong, D., Sack, J., Vogel, A. S., Hodi, F. S., Fong, L. H., Lai, J. C., Zucker, S. D., & Grover, S. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.02.006 · Cited by 10
Moore, R., Ashby, K., Liao, T.-J., & Chen, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182010603 · Cited by 10
Devisscher, L., Campenhout, S. V., Lefere, S., Raevens, S., Tilleman, L., Nieuwerburgh, F. V., Eeckhoutte, H. P. V., Hoorens, A., Lynes, M. A., Geerts, A. M., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0820-527r · Cited by 10
Dinis‐Oliveira, R. J. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1917599 · Cited by 10
Pontikoglou, C. G., Filippatos, T. D., Matheakakis, A., & Papadaki, H. Α. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156000 · Cited by 9
Hou, Y., Gao, Z., Tu, P., Ai, X., & Jiang, Y. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03552 · Cited by 9
Doskey, L. C., Scholtz, C. R., Vail, N. R., Khanal, S., Lee, A. L., Kandanur, S. G. S., Hoell, Z. J., Huehls, A. M., Issa, M. R., Kostallari, E., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02555 · Cited by 9
Yang, R., Zhu, J., Jin, X., Li, Y., Wang, D., & Chao, J. (2025) · Toxicology · doi:10.1016/j.tox.2025.154359 · Cited by 9
AI/ML-based computational models for toxicity prediction
Barua, S., Balaji, B., & Balaji, S. (2026) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-37354-8 · Cited by 9
Critical role of OX40 in drug‐induced acute liver injury
Zhang, C., Jin, H., Wang, Y., Li, C., Zhao, X., Li, Y., Shi, W., Tian, Y., Xu, H., Tian, D., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15041 · Cited by 9
Palbociclib-induced severe hepatitis: A case study and literature review
Hyppolite, J. J., Rho, A., & Hilzenrat, N. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0015 · Cited by 9
Drug-Induced Hepatitis in Children: The Experience of a Single Center in Romania
Dijmărescu, I., Guta, O. M., Brezeanu, L. E., Dijmărescu, A., Becheanu, C. A., & Păcurar, D. (2022) · Children · doi:10.3390/children9081136 · Cited by 9
Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe
Jordan, V. C., Sojoodi, M., Shroff, S. G., Pagan, P. G., Barrett, S. C., Wellen, J. W., Tanabe, K. K., Chung, R. T., Caravan, P. D., & Gale, E. M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100850 · Cited by 9
Shi, W. M., Liu, T., Yang, H., Zhao, J., Wei, Z., Huang, Y., Li, Z., Li, H., Liang, L., Hou, X., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117063 · Cited by 9
Drug-induced autoimmune-like hepatitis
García‐Cortés, M., Pinazo-Bandera, J. M., Lucena, M. I., & Andrade, R. J. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000172 · Cited by 9
Self-citationTienforti, D., Savignano, G., Spagnolo, L., Giulio, F. D., Baroni, M. G., & Barbonetti, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02418-y · Cited by 9
Li, Z.-B., Chen, D., Jia, Y., He, Q., Cui, L., Du, F.-X., Kang, Y., Feng, X., He, M. L., Jin, X., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1413589 · Cited by 9
Retrospective analysis of clinical features of liver injury induced by levofloxacin
Wu, Z., Sun, W., & Wang, C. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2494685 · Cited by 9
Drug Liver Injury Induced by Olmesartan Mediated by Autoimmune-Like Mechanism: A Case Report
de la Torre‐Aláez, M., & Iñarrairaegui, M. (2020) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2020_001407 · Cited by 9
Lee, F. Y., Wong, H., Chan, H., Ali, N. M., Hassan, M. R. A., Omar, H., & Mutalib, N. A. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5153 · Cited by 9
Shah, J., Muir, J., Furfaro, D. M., Beitler, J. R., & Dzierba, A. L. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211034007 · Cited by 9
Li, Z.-B., Chen, D., He, Q., Li, L., Zhou, G., Fu, Y., Deng, Y., Niu, X.-X., Chu, F., Gao, X.-P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.734090 · Cited by 9
Li, J., Zhang, J., Xu, X., Fang, W., Qu, S., Jin, F., Zhou, J., Han, X., Raza, H. K., Li, X., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1981859 · Cited by 9
Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19
Bayram, M., Yıldırım, Ö., ÖZMEN, R. S., Soylu, B., Dündar, A., Köksal, A. R., Akarsu, M., Kumbasar, A., & Tabak, Ö. (2021) · Cureus · doi:10.7759/cureus.18166 · Cited by 9
Hermann, R. P., Rockey, D. C., Suzuki, A., Merz, M., & Tillmann, H. L. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16836 · Cited by 9
Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
Mok, K. K. S., Wu, C., Chan, S. L., Wong, G. L., Wong, V. W., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.12.003 · Cited by 9
Fibrinolysis-Mediated Pathways in Acute Liver Injury
Capece, G. E., Luyendyk, J. P., & Poole, L. G. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0044-1779738 · Cited by 9
Tao, E., Zhou, H., Zheng, M., Zhao, Y., Zhou, J., Yuan, J., Yuan, T., & Zheng, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362668 · Cited by 9
Krajnc, E., Visentin, M., Gai, Z., Stieger, B., Samodelov, S. L., Häusler, S., & Kullak-Ublick, G. A. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000120 · Cited by 9
Self-citationHuang, S., Liu, M., Fu, F., Liu, H., He, B., Xiao, D., & Yang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.572444 · Cited by 9
Barré, T., Rojas, T. R., Lacombe, K., Protopopescu, C., Poizot‐Martin, I., Nishimwe, M. L., Zucman, D., Esterle, L., Billaud, É., Aumaître, H., et al. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1884545 · Cited by 9
Zeng, J., Luo, F., Lin, Z., Chen, Y., Wang, X., & Song, Y. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00819-1 · Cited by 9
Shewale, S., Undale, V., Bhalchim, V. M., Desai, S., Shelar, M., Padole, S., Chitlange, S. S., Wawale, V., Parekh, S. S., & Pujari, P. (2022) · Journal of Natural Remedies · doi:10.18311/jnr/2022/28768 · Cited by 9
Huang, J., Zhang, Z., Hao, C., Qiu, Y., Tan, R., Liu, J., Wang, X., Yang, W., & Qu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.804189 · Cited by 9
Lee, S., Song, D., Shin, S., Hong, N., & Rhee, Y. (2022) · Nutrition · doi:10.1016/j.nut.2022.111813 · Cited by 9
Hepatic Safety Considerations in the Use of Ulipristal Acetate for Symptomatic Uterine Fibroids
Semmler, A., de Lange, M. E., Drenth, J. P. H., Vermeer, N. S., Bet, P. M., Huirne, J. A. F., & Hehenkamp, W. J. K. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s273358 · Cited by 8
Engineering liver disease models in vitro: emerging trends and innovations
Rao, Q., Wang, L., Tacke, F., Guillot, A., & Ma, N. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100279 · Cited by 8
Liu, S., Zhou, Y., Wang, Y., Li, C. B., Wang, W., Xu, L., Liu, P., Hu, Q. H., & Wen, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.817370 · Cited by 8
Lv, B., Liu, L., Liu, X., Huang, M., Chen, X., Tang, K., Wang, C., & Chen, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1126765 · Cited by 8
Key CT and MRI findings of drug-associated hepatobiliary and pancreatic disorders
Ichikawa, S., & Goshima, S. (2023) · Japanese Journal of Radiology · doi:10.1007/s11604-023-01505-z · Cited by 8
Mao, Y., Tang, J. T., Lu, Z. H., Shao, M., Zhao, W. F., Zhan, J., Huang, Z. X., Niu, Q. H., Chen, L., Chen, Z. F., et al. (2025) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13337 · Cited by 8
Chen, X., Liu, H., Li, L., Geru, A., Sun, P., Tan, D. S., Chan, M. Y., Foo, R., Fonarow, G. C., Yang, Q., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02645-0 · Cited by 8
Li, D., Dong, J., Xi, X., Huang, G., Li, W., Chen, C., Liu, J., Du, Q., & Liu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.972800 · Cited by 8
Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature
Castellazzi, M. L., Agostoni, C. V., Palella, J. M., Civeriati, D., Marchisio, P., & Nebbia, G. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1051887 · Cited by 8
Hassoun, J., Goossens, N., Restellini, S., Ramer, L., Ongaro, M., Giostra, E., Hadengue, A., Rubbia‐Brandt, L., & Spahr, L. (2023) · JGH Open · doi:10.1002/jgh3.12862 · Cited by 8
Carrascosa, J. M., Vilarrasa, E., Belinchon, I., Herranz, P., Crespo, J., Guimerá, F., & Olveira, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.01.004 · Cited by 8
Lan, Y., Chen, L., Zhu, J., Li, H., & Lin, Z. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5258 · Cited by 8
Risk of acute liver injury following the nirmatrelvir/ritonavir use
Wong, C. K. H., Mak, L., Au, I. C. H., Cheng, W. Y., So, C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., Leung, G. M., & Yuen, M. (2023) · Liver International · doi:10.1111/liv.15673 · Cited by 8
Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series
Bernasconi, E., Biagi, M., Agostino, S. D., Cursaro, C., Felicani, C., Ronconi, E., Franchi, E., Costanzo, A. A. C., Gabrielli, F., Cavicchioli, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102848 · Cited by 8
Imaging of hepato-pancreato-biliary emergencies in patients with cancer
Jajodia, A., Soyer, P. A., Barat, M., & Patlas, M. N. (2023) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2023.11.002 · Cited by 8
Westerdijk, K., Krens, S. D., Steeghs, N., van der Graaf, W. T. A., Tjwa, E. T. T. L., Westdorp, H., Desar, I. M. E., & van Erp, N. P. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04615-7 · Cited by 8
Ma, Q., Yang, W., Wang, L., Ma, L., Jing, Y., Wang, J., & Liu, X. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106037 · Cited by 8
Xia, C., Liu, Y., Yao, H., Zhu, W., Ding, J., & Jin, J. (2020) · Journal of International Medical Research · doi:10.1177/0300060520917569 · Cited by 8
Costa‐Moreira, P., Gaspar, R., Pereira, P., Lopes, S., Canão, P. A., Lopes, J., Carneiro, F., & Macedo, G. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02824-6 · Cited by 8
Drug-Induced Fatty Liver Disease
Pereverzev, A. P., & Ostroumova, O. D. (2020) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2020-8-2-66-76 · Cited by 8
Herb-induced autoimmune-like hepatitis associated with Xiang-tian-guo (Swietenia macrophylla seeds)
Shao, Y., Zhang, Y., Yin, X., Qin, T., Jin, Q., & Wen, X. (2021) · Medicine · doi:10.1097/md.0000000000024045 · Cited by 8
Managing abnormal liver tests in children with inflammatory bowel disease
van Rheenen, P. F. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001045 · Cited by 8
van Asperdt, J. A. A., & de Moor, R. A. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-02820-y · Cited by 8
Rational choice of hepatoprotectors for drug-induced liver injury
Osyodlo, H. V., Boichak, M. P., & Fedorova, O. O. (2022) · GASTROENTEROLOGY · doi:10.22141/2308-2097.56.3.2022.507 · Cited by 8
Du, H., Zhao, S., Zhao, W. T., Fu, N., Li, W., Qin, X.-J., Zhang, Y., Nan, Y., & Zhao, J. (2021) · PubMed · doi:10.14670/hh-18-340 · Cited by 8
Molecular Mechanisms of Hepatotoxicity
Messina, A., & Duclos‐Vallée, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043791 · Cited by 8
Rizqiah, A., & Damayanti, A. (2023) · JOURNAL OF PHARMACY SCIENCE AND TECHNOLOGY · doi:10.30649/pst.v3i2.41 · Cited by 7
Navigating liver toxicity in the age of novel oncological agents
Riveiro‐Barciela, M., & Martin, E. D. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101473 · Cited by 7
Shi, Q., Wu, M., Zhong, J., Chen, C., Huang, Z., Peng, J., Yang, D. F., Zan, X., & Wang, Z. (2025) · Advanced Science · doi:10.1002/advs.202508742 · Cited by 7
Dong, Y., Zhi, Y., Li, X. N., Ma, M., Ye, M., Huang, S., Tang, J. T., Zhong, W., Lei, X., & Mao, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1694436 · Cited by 7
Zhang, Y., Jin, Z., Xu, L., Zhong, Z., Wang, X., Gao, C., & Li, L. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.016 · Cited by 7
Toxicity evaluation of processing Evodiae fructus based on intestinal microbiota
Liang, X., Liu, J., Di, J., Xiao, N., Peng, Y., Tian, Q., & Chen, L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1336777 · Cited by 7
Huang, A., Zhu, Y., Liu, S., Sun, Y. H., Liu, Z., Liang, Q., Zhao, J., Chang, B., Bi, J., Liu, J., et al. (2024) · Liver International · doi:10.1111/liv.15899 · Cited by 7
Self-citationBeretta‐Piccoli, B. T., Mieli‐Vergani, G., & Vergani, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00074-6 · Cited by 7
Yang, Y., Chen, Q., Liu, Z., Huang, T., Hong, Y., Li, N., Ai, K., & Huang, Q. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.08.239 · Cited by 7
Isorhapontigenin alleviates acetaminophen-induced liver injury by promoting fatty acid oxidation
Zha, H., Lv, S., Hu, Y., Xie, Y., Wang, L., Yang, C., Li, G., Gong, S., Li, P., Zhu, D., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167575 · Cited by 7
Li, J., Li, W., Wang, S., Zheng, H., Bao, J., Wang, Y., & Jin, H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119916 · Cited by 7
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes
Blais, J. E., Yan, V. K. C., Chan, E. W., Wong, I. C. K., & Wan, E. Y. F. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.013 · Cited by 7
Takezawa, T., & Uzu, M. (2022) · The Journal of Toxicological Sciences · doi:10.2131/jts.47.39 · Cited by 7
Drug-induced liver injury associated with dacomitinib: A case report
Wang, X., Huang, A., Lü, Y., Gao, S., Hu, W., & Cheng, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.979462 · Cited by 7
Yu, D., Shao, Z., Fu, Y., Tang, X., Chen, Q., & Deng, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015008 · Cited by 7
Ito, T., Mizuno, K., Yamamoto, T., Yasuda, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Hama, M., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14043 · Cited by 7
Deciphering the Molecular Mechanisms of HAART‐Induced Hepatotoxicity
Ezhilarasan, D., Karthick, M., Sharmila, M., Sanjay, S., & Mani, U. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70174 · Cited by 7
Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift®)
Michels, S., Zizer, E., Barth, T. F. E., Wassner, A., Fangerau, T., Taranu, D., Bachhuber, F., Tumani, H., & Şenel, M. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.101948 · Cited by 7
Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient
Xu, Y., & Wu, Y. (2020) · Medicine · doi:10.1097/md.0000000000022572 · Cited by 7
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2021) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2020.07.007 · Cited by 7
Ostroumova, O. D., Борисова, Е. В., Пиксина, Г. Ф., & Павлеева, Е. Е. (2020) · Medical alphabet · doi:10.33667/2078-5631-2020-21-58-68 · Cited by 7
Voiosu, A. M., Roman, A., Pop, R., Boeriu, A. M., Popp, C. G., Zurac, S., Voiosu, T. A., Dobru, D. E., & Mateescu, B. R. (2021) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2021-0027 · Cited by 7
Knowledge of Herbal Medicines – Is a Reverse Bridge Course an Urgent Necessity?
Parikh, P. M. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.08.022 · Cited by 7
Nunes, D. R. D. C. M. A., Breton, M. C., Monteiro, C. S. D. J., & dos Santos, J. L. (2021) · Healthcare · doi:10.3390/healthcare9121630 · Cited by 7
Lunardelli, M. J. M., Becker, M. W., Ortiz, G. X., & Blatt, C. R. (2022) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2022.132.0791 · Cited by 7
Thewjitcharoen, Y., Krittiyawong, S., Nakasatien, S., & Himathongkam, T. (2022) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476221132824 · Cited by 7
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
